DelMar Announces Relocation of Company Headquarters to San Diego Jul 10, 2019 05:30AM
Delmar Pharma (DMPI) Highlights Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials at ASCO 2019 Meetings Jun 3, 2019 08:47AM
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clini Jun 3, 2019 08:45AM
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board May 20, 2019 05:30AM
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results May 15, 2019 05:30AM
View Older Stories

May 7, 2019 04:53PM DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split
May 6, 2019 05:30AM DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference
Apr 4, 2019 05:30AM DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Apr 3, 2019 05:40AM Delmar Pharma (DMPI) Gets Approval from Univ. of Texas MDACC's IRB for Protocol Expansion in Ongoing Phase 2 Clinical Trial of Val-083
Apr 3, 2019 05:30AM DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083
Feb 20, 2019 05:47AM Delmar Pharma (DMPI) Announces Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Feb 20, 2019 05:30AM DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Feb 12, 2019 05:30AM DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results
Feb 7, 2019 05:30AM DelMar Pharmaceuticals Receives Nasdaq Listing Extension
Nov 20, 2018 05:30AM DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
Nov 14, 2018 05:30AM DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
Oct 10, 2018 05:30AM DelMar Announces Further Validation of the Mechanism of Action of VAL-083
Sep 24, 2018 06:00AM DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results
Sep 4, 2018 05:30AM DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor
Jun 26, 2018 06:06AM Delmar Pharma (DMPI) Reports Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM
Jun 26, 2018 06:00AM DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM
Jun 25, 2018 06:06AM Delmar Pharma (DMPI) Names Dr. Napoleone Ferrara to Board
Jun 25, 2018 06:00AM DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
May 22, 2018 05:55AM Delmar Pharma (DMPI) Names Saiid Zarrabian as Full-Time President and CEO
May 22, 2018 05:30AM DelMar Appoints Saiid Zarrabian to Full-Time President and CEO
May 17, 2018 05:30AM DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
Apr 17, 2018 02:02PM Delmar Pharma (DMPI) Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
Apr 17, 2018 02:00PM DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM
Apr 16, 2018 09:04AM Delmar Pharma (DMPI) Announces Multiple Presentations at AACR
Apr 16, 2018 09:00AM DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research
Feb 14, 2018 05:39PM DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results
Dec 26, 2017 05:44AM Delmar Pharma (DMPI) Gramted Fast Track Designation for VAL-083 in Recurrent Glioblastoma
Dec 26, 2017 05:30AM DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma
Nov 21, 2017 03:08PM Delmar Pharma (DMPI) Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at SNO
Nov 21, 2017 03:06PM DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
Nov 13, 2017 06:14PM DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
Nov 7, 2017 04:08PM Delmar Pharma (DMPI) Appoints Saiid Zarrabian as Interim CEO
Nov 7, 2017 04:05PM DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer
Oct 31, 2017 06:38AM Delmar Pharma (DMPI) Presents Data Supporting VAL-083 Combination for Treatment of Solid Tumors including Brain and Ovarian Cancer
Oct 31, 2017 05:30AM DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer
Oct 3, 2017 05:49AM Delmar Pharma (DMPI) Presented Data on Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer at AACR Conference
Oct 3, 2017 05:30AM DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer
Sep 28, 2017 06:50PM DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results
Sep 27, 2017 05:30AM DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
Sep 26, 2017 10:00AM CEO Jeffery Bacha Discusses DelMar’s VOL-083 Clinical Trials and the Major Milestones Ahead
Sep 22, 2017 02:20PM DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market
Sep 20, 2017 03:32PM Delmar Pharma (DMPI) Reports $10M Registered Direct Offering Priced At-The-Market
Sep 20, 2017 03:31PM DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market
Sep 20, 2017 06:24AM Delmar Pharma (DMPI) Receives New Patent on First-in-Class DNA-targeting Agent, VAL-083
Sep 20, 2017 05:30AM DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083
Sep 18, 2017 08:15AM Delmar Pharma (DMPI) Receives FDA Clearance to Initiate Clinical Trials of VAL-083 for Treatment of Ovarian Cancer
Sep 18, 2017 08:00AM DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer
Sep 11, 2017 06:04AM Delmar Pharma (DMPI) Commences Phase 2 Clinical Trial in Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Sep 11, 2017 04:00AM DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
Sep 6, 2017 01:59PM DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017
View Older Stories